medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2015, Number 5

<< Back Next >>

Rev Invest Clin 2015; 67 (5)

Outcomes of Substituting Oral Fludarabine for Intravenous Fludarabine in Combination with Cytarabine and Filgrastim for Treatment of Primary Refractory or Relapsed Acute Leukemias

Demichelis-Gómez R, Crespo-Solís E, Pérez-Jacobo LF, Valencia-Rocha UR, Rosas-López A

Language: English
References: 49
Page: 287-295
PDF size: 93.62 Kb.


ABSTRACT

Background: Treatment of relapsed/refractory acute myeloid or lymphoid leukemia consists of salvage chemotherapy followed by allogeneic hematopoietic stem-cell transplantation. Intravenous fludarabine, cytarabine, and filgrastim is an effective regimen in this setting. In view of the lack of availability of intravenous fludarabine in Mexico from 2009-2013, we substituted an equivalent oral fludarabine dose (40 mg) for the intravenous formulation. Objective: This is a retrospective comparison of the toxicity and effectiveness of oral fludarabine, cytarabine, and filgrastim versus intravenous fludarabine, cytarabine and filgrastim. Results: A total of 44 patients with relapsed/refractory acute myeloid leukemia or acute lymphoid leukemia treated in an academic medical center from 2005-2013 with oral fludarabine, cytarabine and filgrastim (21 patients) or intravenous fludarabine, cytarabine and filgrastim (23 patients) were included in the analysis. There was a trend towards a higher complete remission rate and a longer overall survival following intravenous fludarabine, cytarabine, and filgrastim as compared with oral fludarabine, cytarabine, and filgrastim: complete remission rates 39.1 vs. 23.8% (p = 0.342) and overall survival 6.14 vs. 10.78 months (p = 0.363), respectively. A higher incidence of neutropenic fever (100 vs. 76.2%; p = 0.019) and septic shock (34.8 vs. 0%; p = 0.003) and a longer hospitalization (26.8 vs. 19.4 days; p = 0.046) were observed with intravenous fludarabine, cytarabine, and filgrastim. In multivariate analysis, factors associated with a shorter survival were septic shock (HR: 3.93; 95% CI: 1.67-9.25; p = 0.002) and a higher number of previous treatments (HR: 2.5; 95% CI: 1.26-4.99; p = 0.009). Complete remission was associated with better survival (HR: 0.18; 95% CI: 0.08-0.44; p ‹ 0.001). Conclusions: Further studies are needed to determine the optimal dose and timing of oral fludarabine when given as part of the fludarabine, cytarabine, and filgrastim regimen for relapsed/refractory acute leukemia. Our data suggest that the dose of oral fludarabine used, 40 mg/m2 per day for five days, may be a lower bioequivalent dose to the intravenous dose in fludarabine, cytarabine, and filgrastim.


REFERENCES

  1. O´Donnell M, Tallman M, Abbod CN, et al. NCCN guidelines version 1.2015. Acute Myeloid Leukemia. National Comprehensive Cancer Network 2015. Available at: http://www.nccn.org/ professionals/physician_gls/pdf/aml.pdf

  2. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Eng J Med. 1994;331:896-903.

  3. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2012;29:532-43.

  4. Gokbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Semin Hematol. 2009;46:64-75.

  5. Sive JI, Buck G, Fielding A, et al. Outcomes in older adults with acute lymphoblastic leukemia (ALL): results for the international MRC UKALL XII/ECOG2993 trial. Br J Hematol. 2012; 157:463-71.

  6. Thomas DA, O´Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursors B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010; 28:3880-9.

  7. Rowe JM, Buck G, Burnett AK, et al.; ECOG; MRC/NRC adult leukemia working party. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106:3760-7.

  8. O´Brien S, Thomas D, Ravandi F, et al. Outcome of adults with acute lymphocytic leukemia after a second salvage therapy. Cancer. 2008;113:3186-91.

  9. Montillo M, Mirto S, Petti MC, et al. Fludarabine, cytarabine, and G-SCF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol. 1998;58:105-9.

  10. Parker JE, Pagliuca A, Mijvic A, et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol. 1997;99:939-44.

  11. Martin MG, Welch JS, Augustin K, et al. Cladribine in the treatment of acute myeloid leukemia: a single-institution experience. Clin Lymphoma Myeloma. 2009;9:298-301.

  12. Wierzbowska A, Robak T, Pluta A, et al. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and GCSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol. 2008;80:115-26.

  13. Amadori S, Arcese W, Isacchi G, et al. Mitoxantrone, etoposide and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of acute myeloid leukemia. J Clin Oncol. 1991;9:1210-4.

  14. Becker PS, Kantarjian HM, Appelbaum FR, et al. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for refractory acute myeloid leukaemia. Br J Haematol. 2011;155:182-9.

  15. Faderl S, Ferrajoli A, Wierda W, et al. Clofarabine combinations as acute myeloid leukemia salvage treatment. Cancer. 2008;113: 2090-6.

  16. Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol. 2006;24:1917-23.

  17. Milano M, Pistorio A, Putti MC, et al. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients. Leuk Lymphoma. 2012; 53:1693-8.

  18. Weiss MA, Aliff TB, Tallman MS, et al. A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia. Cancer. 2002;95:581-7.

  19. Schiller G, Lee M, Territo M, Gajwski J, Nimer S. Phase II study of etoposide, ifosfamide, and mitoxantrone for the treatment of resistant adult acute lymphoblastic leukemia. Am J Hematol. 1993;43:195-9.

  20. DeAngelo DJ, Yu D, Johnson JL, Gajewski J, Nimer S. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group study 19801. Blood. 2007;109:5136-42.

  21. Faderl S, Thomas DA, O´Brien S, et al. Augmented hyper-CVAD based on dosed-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy. Clin Lymphoma Myeloma Leuk. 2011;11:54-9.

  22. Deichter OR, O´Brien S, Deitcher SR, Thomas DA, Kantarjian HM. Single-agent vincristine sulfate liposomes injection (Marqibo) compared to historical single-agent therapy for adults with advanced, relapsed, and/or refractory philadelphia chromosome negative acute lymphoblastic leukemia (abstract). Blood. 2011; 118:2592.

  23. O´Brien S, Schiller G, Lister J, et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, ad refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol. 2012;31:676-83.

  24. Visani G, Tosi P, Zinzani PL, et al. FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of ‘poor risk’ acute myeloid leukemias. Leukemia. 1994;8:1842-6.

  25. Carella AM, Cascavilla N, Greco MM, et al. Treatment of “poor risk” acute myeloid leukemia with fludarabine, cytarabine and G-CSF (flag regimen): a single center study. Leuk Lymphoma. 2001;40:295-303.

  26. Estey E, Plunkett W, Gandhi V, Rios M, Kantarjian H, Keating MJ. Fludarabine and arabinosylcytosine therapy of refractory and relapsed myelogenous leukemia. Leuk Lymphoma. 1992;9: 343-50.

  27. Clavio M, Carrara P, Miglino M, et al. High efficacy of fludarabine- containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Haematologica. 1996;81:513-20.

  28. Nokes TJ, Johnson S, Harvey D, Goldstone AH. FLAG is a useful regimen for poor prognosis adult myeloid leukaemias and myelodysplastic syndromes. Leuk Lymphoma. 1997;27:93-101.

  29. Ferrara F, Melillo L, Montillo M, et al. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation. Ann Hematol. 1999;78:380-4.

  30. Jackson G, Taylor P, Smith GM, et al. A multicentre, open, noncomparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukemia and de novo refractory anemia with excess blasts in transformation. Br J Haematol. 2001;112:127-37.

  31. Hanel M, Friedrichsen K, Hanel A, et al. Mito-FLAG as salvage therapy for relapsed and refractory acute myeloid leukemia. Onkologie. 2001;24:356-60.

  32. Pastore D, Specchia G, Carluccio P, et al. FLAG-IDA in the treatment of refractory/ relapsed acute myeloid leukemia: singlecenter experience. Ann Hematol. 2003;82:231-5.

  33. Steinmetz HT, Schulz A, Staib P, et al. Phase II trial of idarubicin, fludarabine, cytosine arabinoside, and fligrastim (Ida-FLAG) for treatment refractory, relapsed and secondary AML. Ann Hematol. 1999;78:418-25.

  34. Suki S, Kantarjian H, Gandhi V, et al. Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia. Cancer. 1993;72:2155-60.

  35. Montillo M, Tedeschi A, Centurioni R, Leoni P. Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony-stimulating factor (FLAG-GCSF). Leuk Lymphoma 1997;25:579-83.

  36. Specchia G, Pastore D, Carluccio P, et al. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia. Ann Hematol. 2005;84:792-5.

  37. Visani G, Tosi P, Zinzani PL, et al. FLAG (fludarabine, cytarabine, G-CSF) as a second line therapy for acute lymphoblastic leukemia with myeloid antigen expression: in vitro and in vivo effects. Eur J Haematol. 1996;56:308-12.

  38. Foran JM, Oscier D, Orchard J, et al. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "lowgrade" non-Hodgkin’s lymphoma and B-cell chronic lymphocytic leukemia. J Clin Oncol. 1999;17:1574-9.

  39. Oscier D, Orchard J, Culligan D, et al. The bioavailability of oral fludarabine phosphate is unaffected by food. Hematol J. 2001;2:316-21.

  40. Salar A, Domingo-Domenech E, Estany C, et al. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer. 2009;115:5210-6.

  41. Dearden C, Richards S, Else M, Catovsky C, Hilmen P. A comparison if the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial. Cancer. 2010;117:2452-60.

  42. Boogaerts MA, Van Hoof A, Catovsky D, et al. Activity of oral Fludarabine phosphate in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2001;19:4252-8.

  43. Laurenti L, De Padua L, Tarnani M, et al. Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front line therapy in patients affected by chronic lymphocytic leukaemia: influence if biological parameters in the clinical outcome. Ann Hematol. 2011;90: 59-65.

  44. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642-9.

  45. Kantarjian HM, O’Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18:547-56.

  46. Storring JM, Minden MD, Kao S, et al. Treatment of adults with BCR-ABL negative acute lymphoblastic leukemia (ALL) with a modified pediatric regimen. Br J Haematol. 2009;146:76-85.

  47. Arteaga-Ortiz L, Buitrón-Santiago N, Rosas-López A, et al. Acute lymphoblastic leukemia: experience in adult patients treated with hyperCVAD and 0195 Protocol, at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Cohort 2003- 2007. Rev Invest Clin. 2008;60:459-69.

  48. Freilfeld A, Bow E, Sepkowitz K, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by Infectious Diseases Society of America. Clin Infect Dis. 2011;53:e56-93.

  49. Malagola M, Peli A, Damiani D, et al. Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases. Eur J Haematol. 2008;81:354-63.




2020     |     www.medigraphic.com